Concord Biotech Past Earnings Performance
Past criteria checks 3/6
Concord Biotech has been growing earnings at an average annual rate of 13.2%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 11.9% per year. Concord Biotech's return on equity is 20.6%, and it has net margins of 30.2%.
Key information
13.2%
Earnings growth rate
13.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.9% |
| Return on equity | 20.6% |
| Net Margin | 30.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Revenue & Expenses Breakdown
How Concord Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10,857 | 3,279 | 1,300 | 0 |
| 30 Jun 24 | 10,379 | 3,132 | 1,265 | 0 |
| 31 Mar 24 | 10,169 | 3,081 | 1,231 | 0 |
| 31 Dec 23 | 9,706 | 3,046 | 1,178 | 0 |
| 30 Sep 23 | 9,704 | 3,044 | 1,147 | 0 |
| 30 Jun 23 | 8,670 | 2,453 | 1,134 | 0 |
| 31 Mar 23 | 8,532 | 2,401 | 1,103 | 0 |
| 31 Mar 22 | 7,129 | 1,749 | 957 | 0 |
| 31 Mar 21 | 6,169 | 2,349 | 700 | 0 |
| 31 Mar 20 | 5,123 | 1,691 | 624 | 0 |
Quality Earnings: CONCORDBIO has high quality earnings.
Growing Profit Margin: CONCORDBIO's current net profit margins (30.2%) are lower than last year (31.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CONCORDBIO's earnings have grown by 13.2% per year over the past 5 years.
Accelerating Growth: CONCORDBIO's earnings growth over the past year (7.7%) is below its 5-year average (13.2% per year).
Earnings vs Industry: CONCORDBIO earnings growth over the past year (7.7%) did not outperform the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: CONCORDBIO's Return on Equity (20.6%) is considered high.